VERA - VERA

Vera Therapeutics (NASDAQ:VERA) Stock, Quote.Headers.trade-ideas

VERA THERAPEUTICS INC

VERAMARK TECHS INC

Vera Therapeutics

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

VERA

Biotech

News

Health Care

General

Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing.

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CPRX

ORKA

TRNO

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Bernie's Concerns With Healthcare Costs

Long Ideas

RDNT

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics Inc

Vera Bradley Inc

Veracyte Inc

Veradigm Inc

VERALLIA,COURBEVOIE by VERALLIA, COURBEVOIE

Verallia

Veralto Corp

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Verasity

Verastem Inc

Press Releases

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Contracts

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Biohaven

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

GRAIL

Gyre Therapeutics

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Wedbush

Cantor Fitzgerald

HC Wainwright & Co.

JP Morgan

Guggenheim

Comments

Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell